October 12, 2020/Changchun -- The phase Ib/IIa site initiation meeting of TNP-2198 for the treatment of Helicobacter pylori infection was held at the first affiliated hospital of Jilin University. This is a multiple ascending dose study for safety, pharmacokinetic and preliminary efficacy in volunteers who are infected by H. pylori. Professor Yanhua Ding, Director of the Clinical Center and research team from the hospital, TenNor Therapeutics and CROs attended the meeting.

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late stage of clinical development, targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com